A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy
暂无分享,去创建一个
Johan Pallud | Damien Ricard | Jean-Yves Delattre | Michel Tod | Vincent Calvez | Jérôme Honnorat | François Ducray | Benjamin Ribba | F. Ducray | V. Calvez | J. Honnorat | A. Idbaih | B. Ribba | D. Ricard | J. Delattre | E. Grenier | J. Pallud | G. Kaloshi | Ahmed Idbaih | Emmanuel Grenier | Dimitri Psimaras | M. Tod | D. Psimaras | S. Cartalat‐Carel | M. Peyre | B. Cajavec-Bernard | L. Dainese | Gentian Kaloshi | Mathieu Peyre | Branka Cajavec-Bernard | Linda Dainese | Stéphanie Cartalat-Carel
[1] France Mentré,et al. Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide , 2006, Pharmaceutical Research.
[2] J. Murray,et al. Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion , 2003, Journal of the Neurological Sciences.
[3] F. Ducray,et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. , 2010, Neuro-oncology.
[4] B P Booth,et al. Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.
[5] Jan Fagerberg,et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R Grant,et al. Guidelines on management of low‐grade gliomas: report of an EFNS–EANO * Task Force , 2010, European journal of neurology.
[7] G. Williams,et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] C. Daumas-Duport,et al. Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities , 2010, Neurology.
[9] Laurent Capelle,et al. Dynamic history of low‐grade gliomas before and after temozolomide treatment , 2007, Annals of neurology.
[10] B. Kaina. DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. , 2003, Biochemical pharmacology.
[11] G. Williams,et al. Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis , 2001, Neuropathology and applied neurobiology.
[12] M O Karlsson,et al. Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.
[13] Laurent Capelle,et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas , 2003, Annals of neurology.
[14] Kristin R. Swanson,et al. The Evolution of Mathematical Modeling of Glioma Proliferation and Invasion , 2007, Journal of neuropathology and experimental neurology.
[15] Luc Taillandier,et al. Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm , 2008, Neurosurgical Review.
[16] J. Murray,et al. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy , 2002, British Journal of Cancer.
[17] T. Tamiya,et al. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas , 2000, Neuroradiology.
[18] M. Karlsson,et al. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis , 2002, AAPS PharmSci.
[19] D. Bates,et al. Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.
[20] J. Murray,et al. A mathematical model of glioma growth: the effect of chemotherapy on spatio‐temporal growth , 1995, Cell proliferation.
[21] K. Ono,et al. Potentially lethal damage repair by total and quiescent tumor cells following various DNA-damaging treatments. , 1999, Radiation medicine.
[22] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] I. Burney. Cancer Chemotherapy and Biotherapy : Principles and Practice , 2011 .
[24] Albert Lai,et al. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.
[25] R. Gieschke,et al. Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[26] N. Rashevsky,et al. Mathematical biology , 1961, Connecticut medicine.
[27] Nicholas H G Holford,et al. A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non–Small Cell Lung Cancer Patients , 2008, Clinical Cancer Research.
[28] Karsten Wrede,et al. Molecular classification of low-grade diffuse gliomas. , 2010, The American journal of pathology.
[29] France Mentré,et al. The SAEM algorithm for group comparison tests in longitudinal data analysis based on non‐linear mixed‐effects model , 2007, Statistics in medicine.